Amneal Pharmaceuticals, Inc. research snapshot
AMRX AI stock analysis currently views Amneal Pharmaceuticals as a mid-cap generic drug manufacturer with improving fundamentals, a revenue growth trajectory driven by specialty products like CREXONT and injectables, and a net debt position of roughly $2.43 billion that constrains financial flexibility. Q1 2026 revenue grew to $723 million and net income improved to $78 million, continuing the recovery from FY2025 full-year net income of $128 million. At the July 10, 2026 close of $17.01, the stock trades at about 46x trailing EPS (elevated due to depressed TTM earnings of $0.37) but a more reasonable 18.5x forward EPS consensus of $0.92. This AMRX AI stock forecast uses scenarios, not a precise price prediction, and is for informational use only, not investment advice.
Current price
$17.01 close on July 10, 2026
Market cap
$5.43B verified market cap, with $5.43B from the July 10 price times 319.02M shares
AI score
58 / 100
Rating
Mid-cap generic pharmaceutical company with strong revenue growth, a high-margin injectables and specialty portfolio, significant debt leverage, and a recent rally that tests extended valuation
Trend status
Near the upper end of the 52-week range at $17.01, above the 50-day moving average around $14.57, with a strong YTD return of over 35%
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Amneal manufactures and markets generic pharmaceuticals, injectables, biosimilars, and specialty branded drugs, serving retail, institutional, and government customers in the US and globally. | Medium |
| Moat | Moderate. Scale in generics, a broad manufacturing platform, approved ANDA inventory, and specialty neurology products (Rytary, CREXONT) create barriers, but generic pricing erodes moats over time. | Medium |
| Management | Co-founders Chirag and Chintu Modgil serve as co-CEOs, maintaining founder-led alignment. Capital allocation priorities include debt reduction, R&D investment in specialty pipeline, and operational efficiency. | Medium |
| Financial trend | Revenue grew from $2.50B in FY2023 to $3.02B in FY2025. Net income improved from a loss position to $128M in FY2025. Q1 2026 continued the trend with $723M revenue and $78M net income. | High |
| Valuation | At $17.01, the trailing PE of approximately 46x reflects depressed TTM EPS of $0.37, while the forward PE of about 18.5x based on $0.92 consensus EPS is more moderate for the generic pharma peer group. | Medium |
| Technical trend | The July 10 close of $17.01 is about 16.7% above the 50-day moving average of $14.57, within 5% of the 52-week high of $17.86, and well above the 52-week low of $7.66. RSI signals an extended but not exhausted uptrend. | Medium |
| Risk level | Key risks include high net debt of $2.43B, generic pricing pressure, FDA approval risk, product concentration in neurology, potential dilution, and interest expense drag on net income. | Medium-high |
| AI confidence | High confidence in reported financial data, medium confidence in forward scenarios. The 105% one-year rally and forward PE of 18.5x mean the re-rating is partially priced in. | Medium-high data confidence |
| Investment certainty | The bull case requires margin expansion from specialty products and debt reduction to sustain the re-rating. The available evidence supports continued monitoring of Q2 2026 earnings (July 30 release) for confirmation. | Medium |
AMRX AI stock forecast
The AMRX AI stock forecast starts with the $17.01 July 10 close and uses the consensus FY2026 EPS estimate of $0.92 as the forward earnings baseline. The audited three-year scenario model returned approximate anchors of $10.70, $20.70, and $31.80 before dividends, depending on growth, margin expansion, and valuation multiple assumptions.
$28 to $34
More likely if CREXONT and Rytary market share expands, Hopledo is approved in the EU and US, injectables and biosimilars revenue grows, gross margins exceed 40%, net debt declines below $2.0B, and the market awards a forward PE of 18x to 20x.
$18 to $24
More likely if generic and specialty revenue grows at a mid-single-digit to low-double-digit rate, margins stabilize near current levels, the company services debt without strain, and the forward PE settles in the 14x to 18x range.
$9 to $13
More likely if generic pricing deteriorates, a competitor launches a CREXONT alternative, debt refinancing becomes costly, margins compress, or the market re-rates the stock below 12x forward earnings.
AMRX AI technical analysis
AMRX AI technical analysis as of the July 12, 2026 data cutoff shows the stock at $17.01, near the top of its 52-week range and above its 50-day moving average of approximately $14.57. The stock has rallied roughly 105% over the past year, reflecting improving fundamentals and multiple expansion. RSI is in the upper 60s, indicating momentum but not yet extreme overbought territory.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $17.01 | July 10, 2026 closing reference used for valuation and market-cap calculations. |
| Immediate support | $15.50 to $16.00 | The area near the recent consolidation zone before the breakout above $16 in late June. |
| Secondary support | $14.50 to $14.60 | The 50-day moving average near $14.57 often acts as the first major trend-support reference. |
| Near resistance | $17.86 | The 52-week high. A confirmed close above this level opens the path to round-number resistance at $18. |
| Major resistance | $19 to $20 | Round-number psychological zone that also aligns with the UBS price target of $19. |
| Moving averages | 50-day ~$14.57, 200-day ~$12.00 | Price above both averages signals a bullish trend structure. The spread between the 50 and 200-day is wide, suggesting strong momentum. |
| Momentum | RSI in upper 60s | Momentum is positive but approaching levels where rallies may pause or consolidate. |
| Volume | Average volume 2.1M to 2.8M shares | Above-average volume on up days supports the trend. Watch for volume confirmation at resistance tests. |
| Volatility | 52-week range $7.66 to $17.86 | The wide range reflects a significant fundamental turnaround. Expect continued volatility around earnings and FDA news. |
| Invalidation | Sustained close below $14 | A break below the 50-day moving average and the $14 level would suggest the uptrend has paused and warrants a thesis review. |
AMRX AI trading strategy
This AMRX AI trading strategy is a rules-based research framework, not personalized advice. It connects price action with generic and specialty revenue, margins, net debt, debt refinancing, and FDA pipeline updates.
Monitor for a confirmed close above the $17.86 52-week high with volume above the average, alongside evidence that Q2 2026 earnings (July 30 release) show continued revenue growth and that specialty product uptake remains on track.
A failed breakout or a close below $16 should reduce confidence. Reassess if Q2 margins disappoint or debt reduction stalls.
If AMRX pulls back toward the $14.50 to $15.50 range while the fundamental thesis (revenue growth, margin expansion, pipeline progress) remains intact, compare the pullback price with the forward PE of 18.5x and EV/EBITDA of 12.7x before assessing value.
Do not buy a pullback solely on price. A deterioration in generic pricing, debt costs, or pipeline setbacks can make a lower price less attractive rather than a bargain.
Track key catalysts: Q2 2026 earnings (July 30), Hopledo EU and FDA decisions, CREXONT market share data, debt refinancing announcements, and generic ANDA approvals. Each catalyst can drive discrete moves.
Size positions for binary event risk around FDA decisions and earnings. Avoid concentrating exposure ahead of events where the outcome is highly uncertain.
Investment research summary
Customers pay Amneal for affordable generic medicines, high-value injectables, and branded specialty therapies, particularly in neurology (Rytary, CREXONT for Parkinson disease).
Barriers include manufacturing scale, a broad ANDA portfolio, FDA-approved facilities, regulatory expertise, and relationships with retail, institutional, and government buyers. Generic competition erodes moats over time.
The thesis fails if generic pricing pressure accelerates, CREXONT or Rytary faces unexpected competition, Hopledo approval is delayed, debt costs rise, or operating improvements stall before meaningfully reducing leverage.
Founder co-CEOs Chirag and Chintu Modgil have led the company since 2002, demonstrating long-term commitment. Capital allocation focuses on specialty R&D, debt management, and operational scale.
The generic pharmaceutical industry benefits from US healthcare cost-containment demands and an aging population, but faces ongoing pricing headwinds, consolidation, and FDA scrutiny.
At $17.01, the stock trades at about 46x trailing EPS but 18.5x forward consensus EPS. The margin of safety depends on whether management converts specialty pipeline momentum and margin expansion into sustained earnings growth that justifies the current multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| July 10 closing price and market data | $17.01 close, 319.02M shares, $5.43B verified market cap | MarketBeat AMRX statistics | July 12, 2026 |
| Q1 2026 revenue and net income | $723M revenue, $78M net income | MarketBeat AMRX financials | July 12, 2026 |
| FY2025 revenue and net income | $3.019B revenue, $128M net income | MarketBeat AMRX financials | July 12, 2026 |
| Cash, debt, and net debt | $200M cash, $2.63B total debt, $2.43B net debt | MarketBeat AMRX financials | July 12, 2026 |
| Free cash flow FY2025 | $241M operating cash flow minus $99M capex = ~$142M FCF | MarketBeat AMRX cash flow | July 12, 2026 |
| Analyst consensus and price targets | UBS Buy $19, Barclays Overweight $16, Truist Buy $17, consensus Moderate Buy, average target $15.80 | MarketBeat AMRX analyst ratings | July 12, 2026 |
| 52-week range | $7.66 low to $17.86 high | Yahoo Finance AMRX | July 12, 2026 |
| Enterprise value | $7.98B | Yahoo Finance AMRX key statistics | July 12, 2026 |
This AMRX page is an informational research tool, not investment advice or a recommendation to buy or sell. Forecasts are scenarios built from available data and assumptions, can be wrong, and should be checked against current company filings and market conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
